Cancer Cell Biology
Lack of functional erythropoietin receptors of cancer cell lines
Article first published online: 7 NOV 2007
Copyright © 2007 Wiley-Liss, Inc.
International Journal of Cancer
Volume 122, Issue 5, pages 1005–1011, 1 March 2008
How to Cite
Laugsch, M., Metzen, E., Svensson, T., Depping, R. and Jelkmann, W. (2008), Lack of functional erythropoietin receptors of cancer cell lines. Int. J. Cancer, 122: 1005–1011. doi: 10.1002/ijc.23201
- Issue published online: 24 DEC 2007
- Article first published online: 7 NOV 2007
- Manuscript Accepted: 18 JUL 2007
- Manuscript Received: 23 FEB 2007
- Ministry of Science, Economy and Commerce of Schleswig-Holstein. Grant Number: BA 410
- erythropoietin receptor;
- tumor growth;
Erythropoietin (Epo) therapy reduces red cell transfusion requirements and improves the quality of life of anemic cancer patients receiving chemotherapy. However, there is concern that Epo may promote tumor growth. We investigated by real-time RT-PCR, immunofluorescence microscopy, Western blotting and cell growth analysis whether human cancer cell lines (SH-SY5Y, MCF7, HepG2, U2-OS, HeLa, HEK293T, RCC4, HCT116, 7860wt and SW480) possess functional Epo receptors (EpoR). We detected EpoR mRNA in all cell lines. Neither hypoxia nor Epo treatment altered the level of EpoR mRNA expression. Four commonly used commercial antibodies proved to be unsuitable for immunoblot procedures because they cross-reacted with several proteins unrelated with EpoR. Depending on the antibody used, EpoR was localized to the plasma membrane, the cytoplasm or the nucleus. Experiments with small interfering RNA showed that EpoR protein was not expressed by the tumor cells except by UT7/Epo leukemia cells, which served as an EpoR positive control line, and by cells transfected with the human EpoR gene. Apart from UT7/Epo, none of the tumor cell lines responded to Epo treatment with phosphorylation of signaling molecules or with cell proliferation. © 2007 Wiley-Liss, Inc.